SAB Biotherapeutics (SABS) Gains from Sales and Divestitures (2023 - 2025)
Historic Gains from Sales and Divestitures for SAB Biotherapeutics (SABS) over the last 3 years, with Q3 2025 value amounting to $12544.0.
- SAB Biotherapeutics' Gains from Sales and Divestitures fell 5997.83% to $12544.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12544.0, marking a year-over-year decrease of 5997.83%. This contributed to the annual value of $22709.0 for FY2024, which is 7719.26% up from last year.
- Per SAB Biotherapeutics' latest filing, its Gains from Sales and Divestitures stood at $12544.0 for Q3 2025, which was down 5997.83% from $8364.0 recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Gains from Sales and Divestitures ranged from a high of $106250.0 in Q3 2023 and a low of $4183.0 during Q1 2025
- Moreover, its 3-year median value for Gains from Sales and Divestitures was $22843.5 (2024), whereas its average is $32334.7.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first skyrocketed by 7719.26% in 2024, then tumbled by 8179.56% in 2025.
- SAB Biotherapeutics' Gains from Sales and Divestitures (Quarter) stood at $12816.0 in 2023, then surged by 77.19% to $22709.0 in 2024, then plummeted by 44.76% to $12544.0 in 2025.
- Its Gains from Sales and Divestitures stands at $12544.0 for Q3 2025, versus $8364.0 for Q2 2025 and $4183.0 for Q1 2025.